Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells ; volume:17 ; number:1 ; day:7 ; month:3 ; year:2015 ; pages:1-13 ; date:12.2015
Breast cancer research ; 17, Heft 1 (7.3.2015), 1-13, 12.2015
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Min, Ahrum
- Beteiligte Personen und Organisationen
-
Im, Seock-Ah
Kim, Debora Keunyoung
Song, Sang-Hyun
Kim, Hee-Jun
Lee, Kyung-Hun
Kim, Tae-Yong
Han, Sae-Won
Oh, Do-Youn
Kim, Tae-You
O’Connor, Mark J.
Bang, Yung-Jue
SpringerLink (Online service)
- DOI
-
10.1186/s13058-015-0534-y
- URN
-
urn:nbn:de:1111-201702264927
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Min, Ahrum
- Im, Seock-Ah
- Kim, Debora Keunyoung
- Song, Sang-Hyun
- Kim, Hee-Jun
- Lee, Kyung-Hun
- Kim, Tae-Yong
- Han, Sae-Won
- Oh, Do-Youn
- Kim, Tae-You
- O’Connor, Mark J.
- Bang, Yung-Jue
- SpringerLink (Online service)
Ähnliche Objekte (12)
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
PARP inhibitors
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
Entwicklung subtypenselektiver Lysin-Deacetylase-Inhibitoren
Advances and perspectives of PARP inhibitors
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
Der Einfluss des PARP Inhibitors AZD2281 (Olaparib) auf das Wachstum von Mantelzelllymphomen in Abhängigkeit vom ATM und p53 Mutationsstatus
PARP Inhibitors in Ovarian Cancer: A Review
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
PARP inhibitors
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
Entwicklung subtypenselektiver Lysin-Deacetylase-Inhibitoren
Advances and perspectives of PARP inhibitors
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
Der Einfluss des PARP Inhibitors AZD2281 (Olaparib) auf das Wachstum von Mantelzelllymphomen in Abhängigkeit vom ATM und p53 Mutationsstatus
PARP Inhibitors in Ovarian Cancer: A Review
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
PARP inhibitors
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
Entwicklung subtypenselektiver Lysin-Deacetylase-Inhibitoren
Advances and perspectives of PARP inhibitors
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
Der Einfluss des PARP Inhibitors AZD2281 (Olaparib) auf das Wachstum von Mantelzelllymphomen in Abhängigkeit vom ATM und p53 Mutationsstatus